all report title image

Newborn screening has evolved from a simple urine or blood screening test to a more comprehensive and complex screening system capable of detecting over 50 different conditions such as Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, and Maple Syrup Urine Disease (MSUD). Newborn screening tests measure a number of markers in infant’s blood that can be either decreased or increased if an infant has certain diseases. Currently, conditions such as cystic fibrosis (CF), congenital hypothyroidism, phenylketonuria (PKU), and around 22 other metabolic conditions that affect protein or fat metabolism can be diagnosed through newborn screening tests.  

The Asia pacific newborn screening market is estimated to be valued at US$ 308.9 million in 2022 and is expected to exhibit a CAGR of 12.9% during the forecast period (2022-2030).

Figure 1. Asia Pacific Newborn Screening Market Share (%), by End User, 2022

Asia Pacific Newborn Screening  | Coherent Market Insights

Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market

Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in January 2022, Trivitron, medical devices company, informs that implementation of newborn screening at the national level will help to identify the infants who need urgent medical care at a much larger scale. Newborn screening is a program that facilitates the early detection of several genetic, endocrine, and metabolic disorders.

Furthermore, in March 2018, Under National Rural Health Mission, significant progress had been made in reducing mortality in children. Whereas, there is an advance in reducing child mortality there is a dire need to improving survival outcome. This would be reached by early detection and management of conditions that were not addressed comprehensively in the past. Indian Government started the RASHTRIYA BAL SWASTHYA KARYAKRAM (RBSK) in 2019 for the early diagnosis of genetic, endocrine and metabolic disorders. Rashtriya Bal Swasthya Karyakram (RBSK) is an important initiative aiming at early identification and early intervention for children from birth to 18 years to cover 4 ‘D’s namely defects at birth, deficiencies, diseases, development delays including disability.

CMI table icon

Asia Pacific Newborn Screening Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 308.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 12.9% 2030 Value Projection: US$ 815.2Mn
Geographies covered:
  • Asia Pacific: China, Japan, South Korea, ASEAN, India, Australia, Rest of Asia Pacific
Segments covered:
  • By Product Type: Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, Assay Kits and Reagents
  • By Test Type: Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), Others
  • By End User: Hospitals, Maternity & Specialty Clinics, Diagnostic Centers 
Companies covered:

Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.

Growth Drivers:
  • Increasing government initiatives
  • Increasing use of advanced technology for newborn screening 
Restraints & Challenges:
  • Lack of improvement in healthcare infrastructure and trained professionals 

Figure 2. Asia Pacific Newborn Screening Market Share (%), by Countries, 2022

Asia Pacific Newborn Screening  | Coherent Market Insights

Increasing use of advanced technology for newborn screening is expected to drive the market over the forecast period.

Technological advancements in tandem mass spectrometry, colorimetric analysis test, fluorescence analysis test, enzyme or liquid chromatography, and various immunological assays and other analysis and high adoption rate of newborn screening with new technology are factors that are expected to drive growth of the market. In October 2018, LifeCell International, India’s leading stem cell bank and mother & baby diagnostics company, launched RightStart, the world’s first integrated DNA testing for newborn screening to detect over 50 medical conditions.

Asia Pacific Newborn Screening Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, medical screening, nutritional supplements, etc. by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the Asia pacific newborn screening market, owing to the disruption in healthcare services. For instance, in March 2022, according to data published by the National Center for Biotechnology Information, global COVID-19 pandemic has presented extraordinary disruption to healthcare services and exposed them to numerous challenges. Newborn screening (NBS) programmes were also affected; however, scarce data exist on the impact of COVID-19 on NBS. COVID-19 impacted the NBS programs at least partially in most of the responding countries. Majority of the screening centers experienced a broad spectrum of difficulties and were affected to a greater extent in the second wave of the pandemic. Delays and unreliability in the postal service as well as flight cancellations caused delays in sample transport to screening centers. The provision of laboratory equipment and reagent supplies was also affected. The number of staff available to perform screening was reduced due to infection, quarantine or reassignment to COVID-19 wards, sometimes resulting in complete closure of screening laboratories and the need to send the samples to other centers for analysis.

Asia Pacific Newborn Screening Market: Key Developments

In June 2022, PerkinElmer Inc., global corporation focused in the business areas of diagnostics, life science research, food, environmental and industrial testing will host a three-day scientific event exploring the latest advances in newborn screening programs and related technologies. Organized around the theme of ‘Learn, Share and Develop,’ PerkinElmer’s Newborn Screening World View summit will feature more than 20 presentations from participants across 11 countries. Each day, presentations and Q&A sessions scheduled will focus on a different topic, which will include: Newborn screening around the world – discussions around new and expanding programs worldwide, and novel ways to overcome common challenges. Leading the newborn screening conversation – expert advice on optimizing workflow efficiencies, throughput and accuracy, as well as opportunities to expand newborn screening panels. The future of newborn screening – conversations around next generation sequencing, molecular screening and expanding screening techniques and ideas.

Asia Pacific Newborn Screening Market: Restraint

The major factors that hinder growth of the Asia pacific newborn screening market include lack of improvement in healthcare infrastructure and trained professionals. Newborn screening is still not widely adopted in Asia Pacific region and requires more development and awareness. Countries in Asia Pacific region have high population and less number of trained professionals. High population with low and middle-income level and poor quality health services are hindering growth of the market.

Key Players

Major players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.

Newborn screening is a preventative public health initiative which allows detection of disorders early in life before clinical features are present. New-born screening allows these conditions to be detected at birth, allowing the child to potentially lead a normal and healthy life. The test simply requires a few drops of blood, which is collected on a special filter paper by pricking the heel of the baby. Newborn Screening is a comprehensive screening test done for your baby to detect the presence of medical conditions that can be hidden at birth. “Identify the conditions that could be harmful to your baby's growth with Neonatal screening.” Babies need screening during the first few days of life, because some of the conditions found by screening require treatment or intervention right away. NBS happens after birth, usually when your baby is between 24 and 48 hours (1 and 2 days) old. If a baby is tested before 24 hours, they may need to be retested. Screenings are done using the following methods:

  • Blood tests. A few drops of blood are taken from the baby's heel. The blood is sent to a lab for analysis.
  • Hearing test. A health care provider will place a tiny earpiece or microphone in the infant's ear. Another method uses electrodes that are put on the baby's head while the baby is quiet or asleep.
  • CCHD screen. A provider will place a small soft sensor on the baby's skin and attach it to a machine called an oximeter for a few minutes. The oximeter will measure the baby's oxygen levels in the hand and foot.

Market Dynamics

Demand for newborn screening is increasing in order to tackle various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis. According to the World Health Organization (WHO) 2018, globally, around 86% of infants are vaccinated against 26 diseases, however, 19.5 million infants are unvaccinated resulting in death of 2-3 million children every year.

Furthermore, PerkinElmer, Inc., a global corporation focused in the business areas of diagnostics, life science research, in January 2018, announced that it received market authorization from the China Food and Drug Administration (CFDA) to offer its Genetic Screening Processor (GSP) instrument and GSP Neonatal hTSH reagent kit. The GSP instrument is capable of testing for a wide range of disorders using PerkinElmer's dried blood spot assays on a single platform. The GSP is a fully automated, high throughput analyzer that tests neonatal dried blood spot samples to detect potentially life-threatening conditions in newborn babies. The GSP Neonatal hTSH reagent kit aids specifically in the detection of congenital hypothyroidism.

Key features of the study:

  • This report provides an in-depth analysis of the Asia pacific newborn screening market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Asia pacific newborn screening market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Asia pacific newborn screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia pacific newborn screening market

Detailed Segmentation:

  • Asia pacific Newborn Screening Market, By Product Type:
    • Hearing Screening Devices
    • Mass Spectrometer
    • Pulse Oximetry
    • Assay Kits and Reagents
  • Asia pacific Newborn Screening Market, By Test Type:
    • Phenylketonuria (PKU)
    • Critical Congenital Heart Defect (CCHD)
    • Hearing Screening
    • Sickle Cell Disease
    • Maple Syrup Urine Disease (MSUD)
    • Thyroid Disorder
    • Biotinidase Deficiency (BTD)
    • Others
  • Asia pacific Newborn Screening Market, By End User:
    • Hospitals
    • Maternity & Specialty Clinics
    • Diagnostic Centers
  • Asia pacific Newborn Screening Market, By Countries:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Company Profiles
    • Medtronic plc*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Bio-rad Laboratories, Inc.
    • GE Healthcare
    • PerkinElmer, Inc.
    • Waters Technologies Corporation
    • Masimo Corporation
    • Natus Medical Inc.
    • Trivitron Healthcare Pvt. Ltd.
    • ZenTech S.A.
    • Agilent Technologies, Inc.
    • Danaher Corporation (AB SCIEX)

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Asia pacific newborn screening market size is estimated to be valued at US$ 308.9 million in 2022 and is expected to exhibit a CAGR of 12.9% between 2022 and 2030.
Factors such as increasing government initiatives and increasing use of advanced technology for newborn screening are expected to drive the market growth.
Maternity & Specialty Clinics is the leading end user segment in the market. 
The major factors hampering growth of the market include lack of improvement in healthcare infrastructure and trained professionals.
Major players operating in the market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo